Background
SiRNA is widely used for analyzing gene function and target validation in vitro and in recent years has been successfully extended to in vivo research. Integrated DNA Technologies (IDT) synthesizes siRNAs for both in vitro and in vivo applications. Researchers planning in vivo work should be aware that potentially toxic substances can be introduced during oligonucleotide synthesis and purification (HPLC) processes, which must be removed to prevent erroneous results and/or the death of laboratory animals.
Elements of proper manufacturing protocols for siRNA intended for in vivo use that help eliminate toxic substances include:
The Endotoxin Problem
The classic endotoxin is lipopolysaccharide (LPS), a natural product present in the outer membrane of the cell wall of Gram negative bacteria. Toxic LPS is liberated whenever these bacteria die. If present as a contaminant in reagents used in vivo, it can cause severe inflammatory responses and/or death of the animals. In mammals LPS binds to serum proteins and interacts with various receptors on monocytes, macrophages, and endothelial cells. This eventually triggers cytokine production, complement activation, and coagulation cascades.
The majority of endotoxins are liberated when bacteria are lysed. These molecules are particularly difficult to degrade, being composed of a complicated sugar chain and lipid A. Interestingly, the major source of endotoxin contamination in manufacturing is water—in particular, sterile water.
The following guidelines help reduce the chance of LPS contamination of siRNAs intended for in vivo use:
Using these protocols, detectable endotoxin levels for IDT's “in vivo clean siRNAs” are usually in the range of 0.01 to 0.1 EU/mg. This high level of care is needed to produce high quality reagents that are suitable for critical in vivo research and preclinical studies.